Report
Pharmaceuticals: Are anti-IL6 beneficiary to Covid patients?
PharmaceuticalsAre anti-IL6 beneficiary to Covid patients?
Two trial results published on the same day
Sanofi’s trial: more a trend than a real clinical benefit
Positive results for Actemra in a French study
Roche should be the “industrial winnerâ€
Provider
Bryan Garnier
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Jean-Jacques Le Fur
Other Reports from Bryan Garnier
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.